Want to see SG:P8A full AI Analyst Report?
Cordlife Group (P8A) AI Stock Analysis
Cordlife Group
(SGX:P8A)
Cordlife scores low primarily because it remains loss-making and cash-burning: a TTM net loss of about S$10.7m, roughly -29% net margin, negative return on equity and still-negative free cash flow, with revenue around a third below pre-2024 levels. The main mitigating factor is an almost debt-free balance sheet with about S$100m of equity, which limits near-term solvency risk and buys time for the turnaround now showing in narrowing losses and recovering gross margins. Technicals reinforce the caution, with the price well below all key moving averages and negative MACD momentum, while valuation provides no cushion given a negative P/E and no dividend.
Cordlife Group (P8A) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- SGD 32.88M
- Dividend Yield
- ―
- Average Volume (3M)
- 11.38K
- Price to Earnings (P/E)
- -2.2
- Beta (1Y)
- 0.05
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Singapore
- Employees
- 596
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Cordlife Group Business Overview & Revenue Model
Company Description
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its opera...
How the Company Makes Money
Cordlife primarily earns revenue by providing stem cell banking services, typically structured around (1) an upfront service fee covering enrolment, collection kits, logistics, laboratory processing, testing, and cryopreservation setup, and (2) recur...
Cordlife Group Financial Statement Overview
Summary
Cordlife remains deeply unprofitable, with a TTM net loss of about S$10.7m on roughly S$37.0m of revenue (-29% net margin) and an operating loss near S$12.6m. Revenue is still about one-third below pre-2024 levels despite a ~40% FY2025 rebound, and free cash flow stays negative at roughly -S$1.0m after a severe S$15.6m outflow in 2024. The offsetting strength is a fortress balance sheet: minimal debt of S$4.3m versus about S$100m of equity (0.04 debt-to-equity) and S$199m of assets, which funds the turnaround. However, equity has eroded for four consecutive years and return on equity is around -10%, so the safety of the balance sheet is counterbalanced by a broken earnings and cash engine that is only in the early stages of repair.
Income Statement
27NegativeBalance Sheet
71PositiveCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.96M | 38.85M | 27.84M | 55.73M | 55.16M | 56.67M |
| Gross Profit | 20.94M | 21.75M | 11.73M | 37.30M | 37.19M | 39.48M |
| EBITDA | -8.60M | -10.16M | -14.38M | 8.56M | 9.34M | 10.78M |
| Net Income | -10.69M | -12.64M | -18.69M | 3.52M | 4.89M | 6.13M |
Balance Sheet | ||||||
| Total Assets | 198.87M | 201.76M | 217.14M | 228.46M | 228.00M | 233.71M |
| Cash, Cash Equivalents and Short-Term Investments | 49.83M | 51.70M | 60.58M | 65.01M | 65.17M | 64.63M |
| Total Debt | 4.32M | 1.34M | 2.42M | 3.50M | 2.22M | 2.97M |
| Total Liabilities | 98.61M | 97.28M | 98.68M | 92.81M | 93.67M | 97.02M |
| Stockholders Equity | 100.08M | 104.30M | 118.21M | 135.33M | 134.06M | 136.43M |
Cash Flow | ||||||
| Free Cash Flow | -981.00K | -729.00K | -15.62M | 6.96M | 5.32M | 7.93M |
| Operating Cash Flow | -557.00K | 504.00K | -11.31M | 9.80M | 7.71M | 9.50M |
| Investing Cash Flow | 10.13M | 2.77M | -2.81M | -2.63M | 4.43M | -23.91M |
| Financing Cash Flow | -2.91M | -2.10M | 7.17M | -1.86M | -13.45M | 3.37M |
Cordlife Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:P8A, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 7.01 is Positive, neither overbought nor oversold. The STOCH value of 6.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:P8A.
Cordlife Group Peers Comparison
Overall Rating
SG:BSL66Neutral
SG:A5049Neutral- SG:P8A41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SG:BSL | 66Neutral | SGD 1.55B | 22.40 | 6.42% | 3.66% | -3.18% | 6.71% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SG:A50 | 49Neutral | SGD 1.27B | -41.13 | -6.42% | ― | 6.44% | 38.89% |
| SG:P8A | 41Neutral | SGD 23.23M | -2.18 | -10.28% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:P8A | Cordlife Group | 0.09 | -0.07 | -43.13% | |
| SG:BSL | Raffles Medical Group | 0.82 | -0.14 | -14.58% | |
| SG:A50 | Thomson Medical Group Ltd. | 0.05 | -0.01 | -20.00% | |
| SG:40T | ISEC Healthcare Ltd | 0.31 | -0.02 | -6.91% | |
| SG:5WA | OUE Lippo Healthcare Limited | 0.05 | 0.02 | 68.97% | |
| SG:TBDD | Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh | 1.50 | 0.04 | 2.74% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026